Skip to main content
Clinical Trials/NCT05410964
NCT05410964
Completed
Not Applicable

Non-Linear Imaging of Skin In Vivo: VIO In Vivo Skin Imaging evaluatiON (VISION)

Enspectra Health1 site in 1 country122 target enrollmentMarch 28, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Skin Cancer
Sponsor
Enspectra Health
Enrollment
122
Locations
1
Primary Endpoint
VIO System Imaging Performance
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The overall objective of this study is to investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health.

Registry
clinicaltrials.gov
Start Date
March 28, 2018
End Date
August 6, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Enspectra Health
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects, ages 2 - 90 years old.
  • Subject, or guardian, if applicable, must be willing to provide written informed consent prior to enrollment and agree to comply with protocol requirements. If applicable, child must be willing to provide written assent prior to enrollment and agree to comply with protocol requirements.
  • Subject or guardian, if applicable, must have sufficient mental capacity to understand the Informed Consent and provide clinically relevant and reliable feedback regarding their experience with the device.
  • Subject and guardian, if applicable, must comply with the protocol requirements.
  • Subject or guardian, if applicable, must agree that anonymized personal data will be made available to Study Sponsor and requisite regional and international regulatory bodies.

Exclusion Criteria

  • Any general health condition or systemic disease that may represent, in the opinion of the Principal Investigator, a potential increased risk associated with device use
  • Currently infected with a communicable skin infection (e.g., shingles or methicillin-resistant S. aureus), which does not include local and minimally pathogenic or non-pathogenic infections distant from the imaging location(s) (e.g., warts, acne)
  • Any known allergies to any materials used in the preparation of skin and/or device use
  • Has a temporary or permanent electrical implanted medical device

Outcomes

Primary Outcomes

VIO System Imaging Performance

Time Frame: 3 hours

Quantify imaging performance in various types of skin, which may include estimated in vivo resolution and imaging depth. Various types of skin includes skin of different people as well as skin in different locations on the body, and skin with skin disease, including basal cell carcinoma. VIO System device design characteristics were iterated during the study to optimize image quality across subjects with various skin types, body locations, and skin disease states. The outcome measure of device imaging performance (acceptable/not acceptable) was assessed through engineering expert review of VIO images. The engineering expert review determined whether images were of consistent quality.

VIO System Image Quality

Time Frame: 3 hours

Qualitatively evaluate image quality and interpretability by physicians trained in dermatopathology as a function of skin type. VIO System device design characteristics were iterated during the study to optimize image quality across subjects with various skin types, body locations, and skin disease states. The outcome measure of device image quality (acceptable/not acceptable) was assessed through clinical expert review of VIO images. The clinical expert review determined whether VIO images could be interpreted by physicians trained in dermatopathology.

Study Sites (1)

Loading locations...

Similar Trials